{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:41:13Z","timestamp":1790404873973,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":49,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    To determine the value of serum chromogranin A (CgA), a marker of neuroendocrine differentiation, for monitoring prostate cancer; CgA levels were related to three other tumour markers, i.e. total prostate\u2010specific antigen (tPSA), prostatic acid phosphatase (PAP), neurone\u2010specific enolase (NSE), and to testosterone, to assess the importance of hormone withdrawal.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and methods<\/jats:bold>\n                    Serum samples (218) were obtained from 118 patients with prostate cancer, including 111 patients with advanced prostate cancer; 103 presented to our centre for systemic radionuclide therapy of painful skeletal metastases. CgA concentrations were measured using a new immunoradiometric assay (IRMA; Cis Bio International, Gif sur Yvette, France) and a threshold of 70\u2003ng\/mL was determined after receiver operating characteristic curve analysis. Testosterone was also measured with an IRMA assay; tPSA, PAP and NSE were assayed using the time\u2010resolved amplified cryptate emission.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    Serum marker levels were high in 64% of the patients for CgA, 24% for NSE, 89% for tPSA and 81% for PAP. Patients resistant to endocrine treatments and with elevated tPSA (i.e. hormone\u2010independent) showed increased CgA and NSE in 62% and 29%, respectively. Patients with hormone\u2010dependent prostate cancer (i.e. with a normal tPSA level) had elevated CgA in 59% but no abnormal NSE. All patients of the latter group except one showed clinical progression of their disease. However, the mean (\n                    <jats:sc>sd<\/jats:sc>\n                    ) concentrations of CgA in hormone\u2010independent (146) or hormone\u2010dependent (22) patients, at 185.3\u2003(449.1) and 160.9\u2003(293.9)\u2003ng\/mL, respectively, were not statistically different (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.8, Mann\u2013Whitney\n                    <jats:italic>U<\/jats:italic>\n                    \u2010test). For 30 patients, blood samples were drawn and markers measured before and after systemic radionuclide therapy. There was a significant increase in the CgA and tPSA concentrations after treatment (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.0146 and 0.0025, respectively).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    In association with tPSA, serum CgA appears to be a promising marker for monitoring patients with prostate cancer.\n                  <\/jats:p>","DOI":"10.1046\/j.1464-4096.2001.001223.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:05:41Z","timestamp":1047351941000},"page":"790-796","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Serum chromogranin\u2010A in advanced prostate cancer"],"prefix":"10.1111","volume":"88","author":[{"given":"M.","family":"Ferrero\u2010Po\u00fcs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Hersant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pecking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Br\u00e9sard\u2010Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.F.","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(87)80060-6"},{"key":"e_1_2_6_2_2_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0060503"},{"key":"e_1_2_6_2_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19960715)78:2<357::aid-cncr27>3.3.co;2-7"},{"key":"e_1_2_6_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20001115)88:4<652::aid-ijc21>3.3.co;2-t"},{"key":"e_1_2_6_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0045(199602)28:2<98::aid-pros4>3.3.co;2-r"},{"key":"e_1_2_6_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00307937"},{"key":"e_1_2_6_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(95)90002-0"},{"key":"e_1_2_6_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37793-5"},{"key":"e_1_2_6_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990190103"},{"key":"e_1_2_6_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36349-8"},{"key":"e_1_2_6_2_11_2","first-page":"1967","article-title":"The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue","volume":"5","author":"Nakada SY","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_6_2_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01606893"},{"key":"e_1_2_6_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990240308"},{"key":"e_1_2_6_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66261-X"},{"key":"e_1_2_6_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2825(1998)12:1<20::AID-JCLA4>3.0.CO;2-N"},{"key":"e_1_2_6_2_16_2","first-page":"3821","article-title":"Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression","volume":"59","author":"Cox ME","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_6_2_17_2","first-page":"1882","article-title":"Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF\u2010expressing neuroendocrine\u2010differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting","volume":"6","author":"Borre M","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90309-J"},{"key":"e_1_2_6_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1990.71"},{"key":"e_1_2_6_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690013"},{"key":"e_1_2_6_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(91)90257-E"},{"key":"e_1_2_6_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.635"},{"key":"e_1_2_6_2_23_2","first-page":"A1539","article-title":"Serum chromogranin A and TPSA\u2010forms in early stage, untreated prostate cancers","volume":"155","author":"Sokoloff RL","year":"1996","journal-title":"J Urol"},{"key":"e_1_2_6_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0045(19970101)30:1<1::aid-pros1>3.3.co;2-b"},{"key":"e_1_2_6_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00089-1"},{"key":"e_1_2_6_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65203-0"},{"key":"e_1_2_6_2_27_2","first-page":"5663","article-title":"Serum chromogranin A in monitoring metastatic prostate cancer patients","volume":"19","author":"Tarle M","year":"1999","journal-title":"Anticancer Res"},{"key":"e_1_2_6_2_28_2","first-page":"407","article-title":"The role of the androgen receptor in the development and progression of prostate cancer","volume":"26","author":"Jenster G","year":"1999","journal-title":"Semin Oncol"},{"key":"e_1_2_6_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68241-9"},{"key":"e_1_2_6_2_30_2","first-page":"1437","article-title":"Strontium\u201089 and low\u2010dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report","volume":"33","author":"Mertens WC","year":"1992","journal-title":"J Nucl Med"},{"key":"e_1_2_6_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02144-9"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-4096.2001.001223.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-4096.2001.001223.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1464-4096.2001.001223.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:31:14Z","timestamp":1761751874000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1046\/j.1464-4096.2001.001223.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1046\/j.1464-4096.2001.001223.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1464-4096.2001.001223.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]},"assertion":[{"value":"2008-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}